KRT18 and COVID-19: Moreover, TLR2 inhibition protects against SARS-CoV-2–induced lethality in K18-human angiotensin-converting enzyme 2 (K18-hACE2) transgenic mice [18], indicating that TLR2 contributes to disease progression in COVID-19.